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Summary 
This working paper is an in-depth analysis of Gilead Sciences, Inc. Our analysis examines the 
economic factors that impact Gilead’s underlying business and how the firm has adapted to these 
ever-changing factors. This economic analysis is then combined with our proprietary, Hanke-
Guttridge Discounted Cash Flow (HG-DCF) model to determine Gilead’s financial position. The 
HG-DCF model will be presented along-side Monte-Carlo simulations to reveal the distribution 
of probable free cash flows, the likelihood of future earnings, and the degree to which the firm’s 
drug pipeline is being considered by the current market valuation. In addition to these 
quantitative factors, we also examine the compensation plans of Gilead’s executives to assess 
alignment with shareholders. At the conclusion of this analysis, it is our intention for readers to 
understand Gilead’s business plan and the company’s financial standing to arrive at a sound 
investment decision.  
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Rating – Buy – Projected Free Cash Flow per Share: $84.34 
 
Company Name: Gilead Sciences, Inc. 
Fiscal Year ends (current period) : 12/31/2015 (Q2) 
Date: 5/14/2016 
Current Price (2/20/2016):  $                                       82.70              
52-week range: 81.70-123.37 
Market Cap: 110.14 Billion 
Enterprise Value 123.85 Billion 
Total Debt 21,077 Million 
Cash 6,315 Billion 
Net Debt/Enterprise Value 17% 
Dividend Yield: 2.27% 
Diluted Shares Outstanding: 1,412 Million 
P/E ratio: 7.06 
2016 P/E (EPS)  6.66x ($10.10*)  
2015 P/E (EPS)  7.06x ($11.91*)  
2014 EPS  $                                         7.35           
2013 EPS  $                                         1.81  
2012 EPS  $                                         1.64  
P/S ratio: 3.752 
Price-to-book ratio: 8.44 
*Consensus estimates as of the time of this writing.  Source: Bloomberg Terminal 
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Gilead Sciences Inc. (NYSE: GILD) is a biopharmaceutical company that specializes in 
treatments for the human immunodeficiency virus (HIV) and cures for the Hepatitis C virus 
(HCV). The market currently prices GILD at $82.70, which lies in the lower end of the firm's 52-
week range ($81.70 - 123.37). This price is slightly below the probable free cash flow per share, 
$84.34, determined by evaluating the firm with the Hanke-Guttridge Discounted Cash Flow 
model (HG-DCF). While GILD’s newer drugs Sovaldi and Harvoni have been popular, there are 
two elements stinting the company’s confidence: patent expiration dates for many of their drugs 
are near, and competition from rival HCV drugs loom. Further, Sovaldi and Harvoni’s patents 
will expire in 2029.1 As the current market prices appear to entirely discount the firm’s drug 
pipeline and ability to grow through acquisition, our recommendation is to buy GILD. Under the 
stated assumptions about market prices, the firm’s projected cash flow does not take into account 
any possible revenues derived from current pipeline drugs. Thus, if any of its pipeline drugs 
and/or future acquisitions yield viable products, the firm will generate free cash per share in 




GILD is a global biopharmaceutical company, operating in over 30 countries, that focuses on the 
entire drug development process. GILD is part of the S&P 500 with a weight of .3021%, and is 
contained within 96 ETFs. GILD specializes in the human immunodeficiency virus (HIV), 
chronic hepatitis C virus (HCV), and chronic hepatitis B virus (HBV). The company is 
headquartered in Foster City, California. It splits its revenues by geography and product type. 
Geography components include the United States, Europe, among other countries and product 
type is first divided into antiviral products and “other” products. Antiviral products include but 
are not limited to Sovaldi, Atripla, Truvada, Harvoni, Complera/Eviplera, Stribild, and Viread. 
Other products include but are not limited to Letairis, Ranexa, AmBisome, and Zydelig. 
 
In 2012, GILD acquired Pharmasset, Inc, which allowed GILD to create Sovaldi, which was 
approved in 2014.2 In 2013, GILD acquired YM BioSciences Inc, a drug development company 
focused on a candidate for hematologic cancers, momelotinib. After GILD introduced its HCV 
drugs, Sovaldi and Harvoni, in 2013 and 2014 respectively, the company practically doubled in 
size. In 2014, GILD continued to improve their products by reducing drug side effects and 
receiving approval of other drug components such as Tybost and Vitekta. Further, in 2014, GILD 
secured an agreement with Medicines Patent Pool (MPP) to license a generic form of their drug 
to companies in India and China. Research and Development (R&D) expenses have steadily 
been growing from $1.8 billion in 2012 to $2.9 billion in 2014. More recently, in 2016, GILD 
announced its acquisition of Nimbus Apollo, Inc, a company that primarily leads research on 
developing drugs to combat non-alcoholic steatohepatitis (NASH), a serious liver disease 
projected to plague many Americans in the next decade. The firm’s history of acquisitions 
demonstrates that GILD is a capital intensive business.  
 
                                                 
1 2015 GILD 10-K Filing, pp. 14 
2 2015 GILD 10-K Filing, pp. 16 
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GILD has massively outperformed the S&P 500 for the last five years, yielding a ~400% return. 
Analyst recommendations are split between rating GILD a buy (18 ratings) and a hold (10 
ratings), with no sell recommendations (Source: Bloomberg Terminal, function <ANR>). The 
target prices ange from $81 to $135 dollars. The firm’s massive stock gain from ~$20 per share 
in 2011 to ~$80 per share in 2016 has indisputably been driven by the HCV drugs Sovaldi and 
Harvoni. Both are approved for use across multiple genotypes of HCV, as well as some HIV 
cases. Sovaldi and Harvoni have captured the HCV market so well they have left little room for 
growth. Capturing 93% of the current HCV market, Gilead is left with the option to grow by 
acquisition, or by improving their current intellectual property (IP) base through organic R&D.3  
 
GILD’s control of the HCV drug market is not necessarily secure, however. Competing company 
Merck released an HCV drug, Zepatier, priced at $54,600 for a 12-week program. In 
comparison, Harvoni’s list price is $94,600.4 Therefore, due to pricing power, GILD will most 
likely see shrinking revenues from its HCV drugs.  
 
The losses it might suffer due to prices, though, will most likely not keep the company from 
being a buy. GILD’s long term asset turnovers and useful life have been significantly varied over 
the last 5 years due to Gilead’s acquisition of Pharmasset, Inc. in 2012 (Figure 1). Despite the 
massive drop in LTAT due to this acquisition, the $11 billion purchase has proved worthwhile as 






















                                                 
3 "Harvoni Continues To Dominate Hep C Market, Market Continues To Undervalue Gilead." Seeking Alpha. N.p., 
2015. Web. 14 May 2016. <http://seekingalpha.com/article/3066586-harvoni-continues-to-dominate-hep-c-market-
market-continues-to-undervalue-gilead>. 
4 Wasserman, Emily. "UPDATED: Zepatier Beats Harvoni, Sovaldi in Hep C Clinical-data Safety Showdown: 
Advera Health Analytics." Pharma News. N.p., n.d. Web. 14 May 2016. 
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Since 2012, Gilead has improved asset turnovers to ~1.2 as their revenue growth has stalled and 
the company has matured. Going forward, large acquisitions will likely cause huge drops in asset 
turnovers that may take years to recover. For this reason, it was difficult to use the asset turnover 
ratio as a driving parameter in the HG-DCF model.  
 
GILD’s pipeline focuses primarily on the treatment of HIV and liver diseases. New formulations 
of existing tenofovir (TAF), emtricitabine, and other HIV regimens span Phase 1 through 
Marketing Application. Regarding liver diseases, sofosbuvir and velpatasvir formulations are 
tested for treatment of HCV, while Simtuzumab is an antibody being evaluated for the treatment 
of NASH, which is estimated to effect up to 2-3% of the general population.5 The firm also has 
approximately $19 billion of current assets and $13 billion of marketable securities with which it 
may choose to acquire drug companies with promising research without taking on heavy 
amounts of debt. Thus, it seems clear that pipeline and opportunities for growth look strong for 
GILD in the future, despite the short term headwinds in pricing. 
 
Risks and Firm Specific Issues: 
 
 Expiration of drug patents requires the firm to consistently innovate and/or grow by 
acquisition 
 Price competition from competitors 
 Prevalence of diseases treated or cured will heavily influence future demand 




The primary difficulty in modeling Gilead using a discounted cash flow analysis was projecting 
realistic revenue. Therefore, to remain conservative, our revenue projections assume that 
revenues for each drug will drop to zero after the patents on each drug expires. Though this 
estimate is very conservative, we cannot assume that any significant revenues will remain after a 
drug loses protection. If we were to forecast any upside in GILD, the company would be 
significantly undervalued.  In addition, we have assumed that Harvoni and Sovaldi revenues will 
decrease 2% year over year. We have not made assumptions about the value of any of GILD’s 
pipeline drugs. These assumptions help to secure as conservative a model as possible, so that the 
firm’s cash flow performance will be evaluated under pessimistic circumstances. 
 
Cost of goods sold (CoGS), Selling general & administrative (SG&A), and R&D (as % of sales) 
dropped substantially between 2013 and 2014 due to the massive increase in revenues associated 
with the firm’s HCV drugs. Based on our models, these expenses will stay relatively close to 
their most recent three-year values (10%, 11%, and 10.5% respectively). GILD’s effective tax 
rate was approximately 18% last quarter, and even lower in 2014 and 2015. Thus, we estimated 
18% to be a reasonable tax rate for the projection period. We also chose to forgo the standard 
assumption of a 1.5% terminal period revenue growth rate. As we assumed the firm would 
simply be generating cash from its existing IP until the terminal year, Capex was assumed to be 
1.5% of revenue. Lastly, we have a decreasing long-term asset turnover metric for our model, as 
                                                 
5 Bellentani, Stefano, et al. "Epidemiology of non-alcoholic fatty liver disease."Digestive diseases 28.1 (2010): 155-
161. 
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Figure 2 – Results from the Monte-Carlo simulation show the probable free cash per share on the x-axis and the 
frequency with which each value was obtained during the simulation. The current stock price falls in the ~30th 
percentile of the distribution. 
shown in Figure 1. This implies that the firm will become less efficient at generating revenue 
from its non-current assets over time. By assuming this range of pessimistic parameters, the HG-
DCF will provide us with a relatively poor outlook for the firm. If the free cash flow over the 
projection period still looks desirable despite the headwinds we place on it, then the stock is 
likely to be a good investment. 
 
Results and Discussion of Model: 
 
The probable free cash flow per share calculated using the HG-DCF model was $84.33 versus a 
market price of $82.70 (Figure 2). The current price falls in about the 30th percentile for the 
distribution. The model assumptions and GILD’s low deviations in its value drivers, however, 
make the distribution narrow. We see, then, that in the absence of any acquisitions or large 
developments in the pipeline, GILD is likely to produce free cash in excess of its stock price. 
This is dependent on the assumption that GILD will not lose more than 5.5% of their revenue 
(year over year) for the next 10 years. We see this as a reasonable estimate considering that this 
would imply that management will do nothing to remedy hypothetical hemorrhaging revenue for 
up to 10 years.  
 
Our model predicts that long term asset turnovers will decrease to 0.78 by year 10, a relatively 
pessimistic assumption considering they only reached those lows during the doldrums in 2012 
when their purchase of Pharmasset, Inc. had yet to generate revenues. We suspend our concerns 
about this idiosyncrasy because it is derived from a combination of the way in which long-term 
asset turnovers are calculated and the specifics of the pharmaceutical business. Long-term asset 
turnovers are calculated with a quotient of revenues and noncurrent assets. One of the largest 
noncurrent assets for any pharmaceutical company is its intellectual property. Unlike a business 
that relies on its physical assets to help generate revenue, a pharmaceutical company relies 
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Figure 3 – Computation of annual bonus award for GILD Named Executive Officers 
Source: Gilead Sciences, Inc. (2016). Schedule 14A (2016). Retrieved from SEC EDGAR website 
http://www.sec.gov/edgar.shtml 
entirely on its IP, and the drugs derived from it, for its revenue. As mentioned earlier, GILD has 
the option of growing organically or by acquisition. Acquisitions show up as capital 
expenditures, because noncurrent assets increase dramatically. Organic growth is not likely to 
show up on a capital expenditure calculation because those assets are paid for via R&D 
expenses. This is why we have estimated capital expenditures to be low over the coming years. 
We cannot predict when or what effect acquisitions will have, nor can we predict the results of 
the funds spent on R&D. Therefore, we are unable to accurately determine what the long term 
asset turnover of GILD will be in the future. 
 
Proxy Report:  
 
To ensure that management compensation is aligned with the creation of shareholder wealth, we 





Base salary: Fixed annual compensation. The base salaries of GILD named executive officers 
(NEO) in 2015 lay between $865,000 and $1.7 million. 
 
Annual incentives: Consists of cash and stock options based on performance. Payment criteria 
for annual cash bonuses are based 75% on corporate performance and 25% on individual 
performance. The CEO’s bonus, however, is solely based on corporate performance. The graph 





Long-Term Incentive Plan: The long term incentive plan is weighted equally (50%) between 
performance equity rewards and stock options. Performance based equity rewards are given to 
executives based upon an equal weighting of relative total shareholder return (TSR) and absolute 
product revenue as performance metrics. The firm’s TSR is compared to a subset of the S&P 
Healthcare Sub-Index, as detailed below, and the absolute revenue targets established by the 
compensation committee (Figure 4). Additionally, a portion of the equity compensation is 
awarded in the form of stock options. The amounts of these stock options are determined by the 
compensation committee and vest over a four-year period, with a minimum of one year until 
25% of the award may vest. Said options then vest quarterly for the remaining three years. 
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Figure 4 – Net revenue and TSR tranches which dictate the long term incentive compensation of the firm’s 
named executive officers. 
Source: Gilead Sciences, Inc. (2016). Schedule 14A (2016). Retrieved from SEC EDGAR website 
http://www.sec.gov/edgar.shtml 
Figure 5 – Gilead Sciences’ list of comparable companies. 
Source: Gilead Sciences, Inc. (2016). Schedule 14A (2016). Retrieved from 
SEC EDGAR website http://www.sec.gov/edgar.shtml 
 
Stock-ownership guidelines for executive officers: Executive officers of GILD are required to 
maintain stock ownership levels which are determined by multiples of their base salary. The 
CEO is required to hold five times his/her base salary in equity, the President and COO are 
required to hold three time their respective base salaries, and all other named executive officers 
are required to hold two times their annual base salary. 
 






























GILD announced its first dividend in 2015, paying out $1.29 per share in the fiscal year (FY). In 
the first quarter of FY 2016, they announced a $0.43 dividend per share, which, if extended over 
the course of FY 2016 will generate $1.72 per share for shareholders. This firm is likely to 
maintain its dividends going forward as its executives are compensated on a relative TSR metric 
and the firm has more than enough cash and earnings per share to maintain it. 
 
In February 2016, the board of directors authorized a $12 billion repurchase program that 
remains untapped as of March 31, 2016. In 2015, the firm executed $8 billion in share 
repurchases (Figure 6). This can be interpreted as an attitude among the executive members of 





GILD’s management offers no guidance as on future capital expenditures as capital expenditures 
are a function of the firm’s merger and acquisition activity. However, their 2016 guidance 
indicates that they expect the firm’s 2016 revenue to be $30-$31 billion, values less than the 
annualized 2015 revenues in the model.6 This indicates that they expect the revenues of their 
largest revenue contributors to fall in the future.  
 
                                                 
6 Washington, Robin. “Q4 2015 Earnings Results.” Annual Shareholder Presentation. Online. 2 February 2016. Full 
Year 2016 Guidance 
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Figure 7 – Chart of P/E ratio and stock price over the last five years, showing the decrease of the P/E ratio, as 
earnings have soared since 2012. 
Source: Graph Fundamentals function – Bloomberg Terminal. Accessed 5/16/16 . 
Figure 8 – Table of major shareholders of Gilead, showing purchases and sales of shares over the last 5 months.  
Source: Security Ownership function – Bloomberg Terminal. Accessed 5/16/16 . 
Multiples Analysis: 
 
Gilead has an average price-to-earnings (P/E) ratio of 17.30 over the last 5 years (see Figure 7).  
Multiplying the average P/E by their trailing twelve months EPS of $10.10 yields an estimated 
share price of $174.73, more than double the company’s current stock price. This method of 
analysis is skewed towards a higher valuation than is appropriate, though, because Gilead’s 
earnings have increased nearly 300% in three years. Implying that an investor should be willing 
to pay $17.30 per $1 of earnings at this point in the company’s life span does not seem 
reasonable because there is little to justify such a premium on their earnings. Evidence of this is 
found in the firm’s current P/E multiple of 7.58, less than half of the 5-year average P/E ratio. 
 
Insider Transaction Information: 
 
Gilead has been a topic of disagreement among major investors over the last 5 months with more 
sales than buys occurring (Figure 8). This is likely tied to concerns regarding Gilead’s market 
share in the HCV market, and its future ability to maintain such high earnings. 
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Figure 9 – Graph of purchases, sales, and exercised options by firm insiders over the past two years, showing 
favoritism for sales in 2015 and a relatively neutral position in 2016. 




Firm insiders have had a relatively negative outlook on the firm over the past two years, coming 
to a rather neutral or even positive looking position in the last 5 months. Given lowered earnings 
expectations, it appears that the firm’s insiders have a more bullish outlook on the stock price 




The firm’s projected free cash flow per share is equal to its stock price when we assume that all 
revenues will drop to zero after IP expiration occurs, indicating that the market is most likely 
assuming such behavior will take place. GILD will either have to organically develop or 
purchase other IP that will be able to improve its current $30 billion revenue well past 2030 
(when Harvoni and Sovaldi expire). Given that the firm’s current valuation appears to solely 
consider the firm’s current drug arsenal, any innovations or acquisitions that generate positive 
cash flow will improve the valuation of GILD. With its current high profits, GILD can evaluate 
acquisition opportunities rigorously and pursue organic drug development concurrently. 
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Management is incentivized to improve overall revenues while focusing equally on the 
shareholder benefits. The value thesis of GILD resides on our belief in the firm to use its vast 
resources to make any intelligent improvements to the firm at all. Therefore we rate the stock a 
buy.  
